- 新光藥業
- 15.210-0.200 (-1.298%)
盈利能力分析
- 5.467
- 6.018
- 7.558
- 12.764
- 13.660
- 5.028
- 5.477
- 6.817
- 11.514
- 12.536
- 5.450
- 6.000
- 7.534
- 12.721
- 13.613
邊際利潤分析
- 39.123
- 33.828
- 41.274
- 51.853
- 55.705
- 26.759
- 21.425
- 27.416
- 36.019
- 41.319
- 20.689
- 14.324
- 20.070
- 32.956
- 35.951
- 22.049
- 18.826
- 23.800
- 30.960
- 35.615
收益指標分析
- 93.954
- 88.060
- 91.070
- 96.510
- 95.324
- 5.465
- 8.542
- 5.567
- 3.436
- 4.863
- -2.708
- -0.596
- -1.330
- -0.797
- -0.474
償債能力分析
- 13.410
- 10.972
- 10.186
- 9.192
- 10.448
- 12.354
- 9.990
- 9.260
- 8.670
- 9.826
- 7.327
- 8.711
- 9.274
- 10.322
- 9.243
- -0.662
- -0.746
- -0.790
- -0.878
- -0.950
- -15,058.529
- -13,370.649
- -12,626.621
- -11,355.291
- -10,495.163
- 1,264.859
- 1,047.996
- 978.294
- 868.758
- 981.841
- -3.857
- -2.054
- -2.873
- -11.862
- -6.950
營運能力分析
- 16.307
- 14.654
- 22.496
- 20.345
- 19.610
- 139.982
- 143.048
- 133.264
- 98.820
- 113.577
回顧25 展望26
貨幣攻略
More